Author Contributions
Conceptualization, A.A. and M.I.; methodology, A.A.; software, W.A.A.; validation, A.A., D.M.B. and M.A.; formal analysis, D.M.B.; investigation, A.A.; resources, W.A.A.; data curation, M.A.; writing—original draft preparation, A.A.; writing—review and editing, M.I.; visualization, D.M.B.; supervision, M.I.; project administration, M.I.; funding acquisition, W.A.A. All authors have read and agreed to the published version of the manuscript.
Figure 1.
Structures of (A) Irbesartan, (B) Soluplus®, (C) Kollidon® VA 64, (D) PVP-K30, and (E) Kolliphor® P 407.
Figure 1.
Structures of (A) Irbesartan, (B) Soluplus®, (C) Kollidon® VA 64, (D) PVP-K30, and (E) Kolliphor® P 407.
Figure 2.
(A) Preparation of binary solid dispersions, (B) Preparation of ternary solid dispersions.
Figure 2.
(A) Preparation of binary solid dispersions, (B) Preparation of ternary solid dispersions.
Figure 3.
Saturation solubility data of pure Irbesartan and solid dispersions in (a) pH 6.8 phosphate buffer, (b) 0.1 N HCl (pH 1.2) (n = 3, mean ± SD).
Figure 3.
Saturation solubility data of pure Irbesartan and solid dispersions in (a) pH 6.8 phosphate buffer, (b) 0.1 N HCl (pH 1.2) (n = 3, mean ± SD).
Figure 4.
Dissolution profile of binary solid dispersions prepared with Soluplus® in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 4.
Dissolution profile of binary solid dispersions prepared with Soluplus® in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 5.
Dissolution profile of pure Irbesartan and binary solid dispersions prepared with Kollidon® VA 64 in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 5.
Dissolution profile of pure Irbesartan and binary solid dispersions prepared with Kollidon® VA 64 in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 6.
Dissolution profile of pure Irbesartan and ternary solid dispersions prepared with Kolliphor® P 407 in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 6.
Dissolution profile of pure Irbesartan and ternary solid dispersions prepared with Kolliphor® P 407 in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 7.
Dissolution profile of pure Irbesartan and ternary solid dispersions formulated with PVP- K30 in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 7.
Dissolution profile of pure Irbesartan and ternary solid dispersions formulated with PVP- K30 in (a) pH 6.8 phosphate buffer (b) 0.1 N HCl (n = 3, mean ± SD).
Figure 8.
SEM micrographs of (A,B) pure Irbesartan, (C) S1, (D) K4, (E) KP407 (TD3), and (F) KPVP (TD3) formulations.
Figure 8.
SEM micrographs of (A,B) pure Irbesartan, (C) S1, (D) K4, (E) KP407 (TD3), and (F) KPVP (TD3) formulations.
Figure 9.
PXRD data of (A) Irbesartan and binary solid dispersions: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) binary solid dispersion of drug and Kollidon® VA 64 at ratio 1:4 [K4], (d) Soluplus®, (e) binary dispersion of drug and Soluplus® at ratio 1:1 [S1]. (B) Irbesartan and ternary solid dispersions: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) Kolliphor® P 407, (d) Polyvinylpyrrolide- K30, (e) ternary solid dispersion KP407 (TD3), (f) ternary solid dispersion KPVP (TD3).
Figure 9.
PXRD data of (A) Irbesartan and binary solid dispersions: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) binary solid dispersion of drug and Kollidon® VA 64 at ratio 1:4 [K4], (d) Soluplus®, (e) binary dispersion of drug and Soluplus® at ratio 1:1 [S1]. (B) Irbesartan and ternary solid dispersions: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) Kolliphor® P 407, (d) Polyvinylpyrrolide- K30, (e) ternary solid dispersion KP407 (TD3), (f) ternary solid dispersion KPVP (TD3).
Figure 10.
FTIR data of (A) Soluplus®-based solid dispersion formulation: (a) pure Irbesartan, (b) Soluplus®, (c) binary system of drug and Soluplus® at ratio 1:1 [S1]. (B) Kollidon® VA 64-based solid dispersion formulation: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) binary solid dispersion of drug and Kollidon® VA 64 at ratio 1:4 [K4]. Note: Background noise may be present along with signals of compounds in FTIR display.
Figure 10.
FTIR data of (A) Soluplus®-based solid dispersion formulation: (a) pure Irbesartan, (b) Soluplus®, (c) binary system of drug and Soluplus® at ratio 1:1 [S1]. (B) Kollidon® VA 64-based solid dispersion formulation: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) binary solid dispersion of drug and Kollidon® VA 64 at ratio 1:4 [K4]. Note: Background noise may be present along with signals of compounds in FTIR display.
Figure 11.
FTIR data of (A) Kolliphor® P 407-based ternary solid dispersions formulation: (a) pure Irbesartan, (b) Kolliphor® P 407, (c) Kollidon® VA 64, (d) ternary system KP407 (TD3). (B) Polyvinylpyrrolidone-K30-based ternary solid dispersions formulation: (a) pure Irbesartan, (b) Polyvinylpyrrolidone-K30, (c) Kollidon® VA 64, (d) ternary solid dispersion KPVP (TD3). Note: Background noise may be present along with signals of compounds in FTIR display.
Figure 11.
FTIR data of (A) Kolliphor® P 407-based ternary solid dispersions formulation: (a) pure Irbesartan, (b) Kolliphor® P 407, (c) Kollidon® VA 64, (d) ternary system KP407 (TD3). (B) Polyvinylpyrrolidone-K30-based ternary solid dispersions formulation: (a) pure Irbesartan, (b) Polyvinylpyrrolidone-K30, (c) Kollidon® VA 64, (d) ternary solid dispersion KPVP (TD3). Note: Background noise may be present along with signals of compounds in FTIR display.
Figure 12.
DSC curves of (A) Irbesartan and binary solid dispersions: (a) pure Irbesartan, (b) Soluplus®, (c) Kollidon® VA 64, (d) binary dispersion of drug and Soluplus® at ratio 1:1 [S1], (e) binary solid dispersion of drug and Kollidon® VA 64 at ratio 1:4 [K4]. (B) Irbesartan and ternary solid dispersions: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) Kolliphor® P 407, (d) Polyvinylpyrrolide- K30 (PVP-K30), (e) ternary solid dispersion KP407 (TD3), (f) ternary solid dispersion KPVP (TD3).
Figure 12.
DSC curves of (A) Irbesartan and binary solid dispersions: (a) pure Irbesartan, (b) Soluplus®, (c) Kollidon® VA 64, (d) binary dispersion of drug and Soluplus® at ratio 1:1 [S1], (e) binary solid dispersion of drug and Kollidon® VA 64 at ratio 1:4 [K4]. (B) Irbesartan and ternary solid dispersions: (a) pure Irbesartan, (b) Kollidon® VA 64, (c) Kolliphor® P 407, (d) Polyvinylpyrrolide- K30 (PVP-K30), (e) ternary solid dispersion KP407 (TD3), (f) ternary solid dispersion KPVP (TD3).
Table 1.
Composition of binary and ternary solid dispersions.
Table 1.
Composition of binary and ternary solid dispersions.
Formulation Code (Binary Solid Dispersions) | Composition (Drug: Polymer), w/w |
---|
S1 | 1:1 |
S2 | 1:2 |
S3 | 1:3 |
S4 | 1:4 |
K1 | 1:1 |
K2 | 1:2 |
K3 | 1:3 |
K4 | 1:4 |
Formulation code (Ternary solid dispersions) | Composition (Drug: Kollidon® VA 64: ternary polymer ), w/w/w |
KP407 (TD1) | 1:4:1 |
KP407 (TD2) | 1:4:2 |
KP407 (TD3) | 1:4:3 |
KPVP (TD1) | 1:4:1 |
KPVP (TD2) | 1:4:2 |
KPVP (TD3) | 1:4:3 |
Table 2.
Relationship of n value with release mechanism.
Table 2.
Relationship of n value with release mechanism.
N | Release Mechanism |
---|
0.45 or less | Fickian diffusion |
0.45–0.89 | Non Fickian or anomalous mechanism |
0.89 | Case II transport |
>0.89 | Super case II transport |
Table 3.
Screening data of Irbesartan with different polymers at various concentrations.
Table 3.
Screening data of Irbesartan with different polymers at various concentrations.
Carrier Concentration, % | 1a | 2a | 3a | 4a |
---|
Soluplus® | 162.24 ± 1.87 | 106.16 ± 1.87 | 67.53 ± 2.85 | 59.43 ± 1.87 |
Kollidon® VA 64 | 170.34 ± 1.079 | 190.90 ± 1.079 | 230.15 ± 1.079 | 282.49 ± 2.15 |
PVP-K30 | 110.52 ± 5.39 | 115.51 ± 1.86 | 134.20 ± 1.86 | 172.21 ± 2.85 |
Kolliphor® P 407 | 96.19 ± 3.89 | 109.90 ± 4.94 | 120.49 ± 4.31 | 169.71 ± 1.87 |
PEG 6000 | 70.03 ± 5.39 | 23.30 ± 3.89 | 25.79 ± 1.87 | 12.71 ± 1.87 |
HPMC E5 | 33.89 ± 4.70 | 50.09 ± 1.86 | 61.30 ± 1.86 | 77.50 ± 1.079 |
Gelucire® 50/13 | 30.77 ± 2.15 | 27.04 ± 1.079 | ------- b | -------- b |
Table 4.
Drug content and % yield data of binary and ternary solid dispersion formulations.
Table 4.
Drug content and % yield data of binary and ternary solid dispersion formulations.
Formulation | Drug Content, % | Yield, % |
---|
S1 | 92.89 | 92.00 |
S2 | 82.03 | 82.11 |
S3 | 87.88 | 84.55 |
S4 | 81.20 | 85.00 |
K1 | 86.21 | 90.00 |
K2 | 90.39 | 87.00 |
K3 | 86.21 | 88.00 |
K4 | 93.73 | 94.67 |
KP407 (TD1) | 91.22 | 88.22 |
KP407 (TD2) | 93.73 | 90.00 |
KP407 (TD3) | 94.56 | 94.00 |
KPVP (TD1) | 90.39 | 85.00 |
KPVP (TD2) | 92.89 | 90.00 |
KPVP (TD3) | 94.56 | 94.00 |
Table 5.
Kinetic modelling data of prepared solid dispersion formulations from drug release in pH 6.8 phosphate buffer.
Table 5.
Kinetic modelling data of prepared solid dispersion formulations from drug release in pH 6.8 phosphate buffer.
Formulaion Codes | Zero Order | First Order | Higuchi Model | Hixon-Crowell | Krosmeyer–Peppas |
---|
(R2) | (R2) | (R2) | (R2) | (R2) | n |
---|
S1 | 0.44 | 0.29 | 0.61 | 0.10 | 1.00 | 0.18 |
S2 | 0.53 | 0.73 | 0.97 | 0.67 | 1.00 | 0.39 |
S3 | 0.43 | 0.63 | 0.94 | 0.57 | 0.99 | 0.36 |
S4 | 0.16 | 0.41 | 0.86 | 0.34 | 0.99 | 0.29 |
K1 | 0.70 | 0.04 | 0.57 | 0.13 | 0.97 | 0.17 |
K2 | 0.03 | 0.51 | 0.79 | 0.36 | 0.99 | 0.25 |
K3 | 0.10 | 0.46 | 0.76 | 0.31 | 0.99 | 0.23 |
K4 | 0.08 | 0.57 | 0.83 | 0.45 | 1.00 | 0.04 |
KP407 (TD1) | 0.51 | 0.33 | 0.03 | 0.67 | 1.00 | 0.04 |
KP407 (TD2) | 0.51 | 0.34 | 0.14 | 0.04 | 0.99 | 0.07 |
KP407 (TD3) | 0.51 | 0.60 | 0.03 | 0.01 | 1.00 | 0.04 |
KPVP (TD1) | 0.56 | 0.02 | 0.09 | 0.25 | 1.00 | 0.06 |
KPVP (TD2) | 0.55 | 0.50 | 0.07 | 0.06 | 1.00 | 0.06 |
KPVP (TD3) | 0.54 | 0.74 | 0.03 | 0.10 | 1.00 | 0.05 |
Table 6.
Kinetic modelling data of prepared solid dispersion formulations from drug release data in 0.1 N HCl.
Table 6.
Kinetic modelling data of prepared solid dispersion formulations from drug release data in 0.1 N HCl.
Formulaion Codes | Zero Order | First Order | Higuchi Model | Hixon-Crowell | Krosmeyer–Peppas |
---|
(R2) | (R2) | (R2) | (R2) | (R2) | n |
---|
S1 | 0.92 | 0.30 | 0.37 | 0.10 | 0.99 | 0.12 |
S2 | 0.17 | 0.50 | 0.74 | 0.33 | 0.99 | 0.22 |
S3 | 0.11 | 0.54 | 0.84 | 0.42 | 0.98 | 0.27 |
S4 | 0.89 | 0.70 | 0.94 | 0.62 | 0.99 | 0.35 |
K1 | 0.56 | 0.13 | 0.56 | 0.07 | 0.99 | 0.16 |
K2 | 0.38 | 0.71 | 0.91 | 0.63 | 0.97 | 0.33 |
K3 | 0.50 | 0.78 | 0.93 | 0.72 | 0.97 | 0.37 |
K4 | 0.54 | 0.33 | 0.02 | 0.73 | 1.00 | 0.04 |
KP407 (TD1) | 0.67 | 0.34 | 0.71 | 0.74 | 1.00 | 0.05 |
KP407 (TD2) | 0.54 | 0.74 | 0.06 | 0.15 | 1.00 | 0.05 |
KP407 (TD3) | 0.51 | 0.93 | 0.71 | 0.08 | 1.00 | 0.04 |
KPVP (TD1) | 0.56 | 0.58 | 0.13 | 0.22 | 1.00 | 0.07 |
KPVP (TD2) | 0.48 | 0.93 | 0.12 | 0.70 | 1.00 | 0.02 |
KPVP (TD3) | 0.52 | 0.96 | 0.00 | 0.11 | 1.00 | 0.04 |